AI주식인사이트AI Stock Insight
C

뷰노

338220KOSDAQ

54.3 / 100

Reference Date: 2026-09-08

Financial Score19.0 / 40
News Sentiment16.3 / 25
Momentum7.0 / 20
Disclosure12.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 34.2% over the past month, and news sentiment is negative.

Company InformationBased on 2025 Annual Report

Business Overview

VUNO is a pioneer in medical IT, leveraging deep learning to provide innovative solutions such as cardiac arrest prediction, fundus image analysis, and chest X-ray diagnostics. Its key product, VUNO Med-DeepCARS, received FDA Breakthrough Device Designation in 2023 and is actively expanding into the U.S. market. The company is transitioning to a SaaS-based subscription model, with the prognosis and prediction solutions driving the majority of its revenue.

Number of Employees

165people

Average Salary

80.5M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
2.03Industry Average 1.201.0Point

1.7x industry avg (risky)

ROE
-17.30Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
5.13Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲64.8% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲40.5% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -74.0% (improving, 3yr)

Detailed News Sentiment

13 totalPositive 4Neutral 3Negative 6Average Sentiment Score 65

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 5,240Won52-week high 27,60052-week low 5,210
1-month return0.0Point

1m -34.25% (strong drop)

Volume trend6.0Point

Volume surge

Detailed Disclosure

6 totalPositive 1Neutral 5Negative 0
  • Neutral합병등종료보고서(자산양수도)2026-09-04
  • Neutral주식등의대량보유상황보고서(일반)2026-09-04
  • Positive주요사항보고서(유상증자결정)2026-08-28
  • Neutral증권신고서(지분증권)2026-08-28
  • Neutral전환사채(해외전환사채포함)발행후만기전사채취득2026-08-26